美邦股份 (605033)
Shaanxi Meibang Pharmaceutical Group Co., Ltd.
K-Line Chart
No K-line data available
Company NameShaanxi Meibang Pharmaceutical Group Co., Ltd.
Listing Date2021-09-16
Issue Price12.69RMB
Registered Capital1352010k RMB
Legal RepresentativeZhang Shaowu
Registered AddressPucheng High-tech Industrial Development Zone, Weinan City, Shaanxi Province
IndustryAgrochemical Products
Main BusinessResearch, development, production, and sales of pesticide formulations
Company ProfileShaanxi Meibang Pharmaceutical Group is headquartered in the Economic and Technological Development Zone of Xi'an, Shaanxi Province. Founded in 1998, the company is a modern agricultural high-tech enterprise integrating pesticide R&D, production, sales, and agricultural technology extension services. The company focuses on the development of new pesticide products and the formulation, application, and implementation of core plant disease and pest control solutions. Its product line covers insecticides, fungicides, acaricides, plant growth regulators, and various other products, possessing the capability for full-crop cultivation and solving crop-related issues. The group has eight subsidiaries, including Shaanxi Thompson Biotechnology Co., Ltd., Shaanxi Nuozheng Biotechnology Co., Ltd., Shaanxi Asia-Pacific Testing and Evaluation Co., Ltd., and Shaanxi Federal Testing Technology Service Co., Ltd.
The company's technology center was recognized as a Shaanxi Provincial Enterprise Technology Center in 2014. Currently, the group holds 957 pesticide registration certificates and has been granted 299 valid national invention patents. The company has been recognized as a 'National Intellectual Property Demonstration Enterprise,' a 'High-Tech Enterprise,' and a 'Key Leading Enterprise in Shaanxi's Agricultural Industrialization.' It has also received honors such as 'China's Top 100 Pesticide Enterprises,' 'China's Top 20 Pesticide Formulation Enterprises,' and 'National Intellectual Property Advantage Cultivation Enterprise.'
Stock Details
1. Key Indicators
- Total Shares(W): 13520.00
- Circulating A-Shares(W): 13520.00
- Earnings Per Share(RMB): 0.2700
- Net Assets Per Share(RMB): 8.4862
- Operating Revenue(W RMB): 60888.57
- Total Profit(W RMB): 3630.15
- **Net Profit Attributable to Parent(W RMB) **: 3619.61
- Net Profit Growth Rate(%): -16.36
- Weighted Return on Equity(%): 3.1800
- Operating Cash Flow Per Share(RMB): 0.4970
- Undistributed Profit Per Share(RMB): 3.8775
- Capital Reserve Per Share(RMB): 3.3977
2. Main Business
The main business covers:
- Research, development, production, and sales of pesticide formulations
3. Company Basic Information
- Company Name: Shaanxi Meibang Pharmaceutical Group Co., Ltd.
- Listing Date: 2021-09-16
- Industry: Chemical Raw Materials and Chemical Products Manufacturing
- Address: Pucheng County High-tech Industrial Development Zone, Weinan City, Shaanxi Province
- Website: https://www.meibang.cn
- Company Profile: The company was established through the overall change of Meibang Co., Ltd. into a joint stock company. On September 9, 2018, Meibang Co., Ltd. passed a resolution at the shareholders' meeting, and all shareholders unanimously agreed to convert the audited net assets of Meibang Co., Ltd. as of July 31, 2018, amounting to RMB 184,725,919.15, into 98.40 million shares at a ratio of 1:0.5327, thereby establishing a joint stock company through an overall change.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Lianyungang Tongmei Enterprise Management Co., Ltd. | Corporate Entity | 900.00 | 6.66 |
| 2 | Lianyungang Meifu Enterprise Management Consulting Partnership (Limited Partnership) | Corporate Entity | 416.58 | 3.08 |
| 3 | Lianyungang Meiping Enterprise Management Consulting Partnership (Limited Partnership) | Corporate Entity | 226.13 | 1.67 |
| 4 | UBS AG | QFII | 58.81 | 0.44 |
5. Concept Sectors
- Rural Revitalization
- Pest Control
- Small Cap Non-Margin
- Micro and Small Cap Stocks
- SSE Innovation
Remarks
- Data update date: 2025-09-30
- Data source: Public Market Information